Skip to content
Back to browse
LIVER Publication-derived

Hepatoblastoma Liver Organoids for Transplantation

Full SOP with Academic or a plan

Source Yang et al. · Obstetrics and Gynecology Hospital of Fudan University

Authors: Yang et al. Duration: 21 days 14 phases Cell source: Human Fetal Liver Hepatoblasts

Abstract

This protocol describes the isolation and culture of human fetal liver organoids from elective abortion tissues, followed by lentiviral-mediated manipulation to model hepatoblastoma development. YAP1 activation in organoids recapitulates hallmarks of hepatoblastoma and enables in vivo tumorigenesis studies in xenograft models.

Cell source
Human Fetal Liver Hepatoblasts
Application
Disease modeling (Hepatoblastoma)

Protocol overview

63 steps across 14 phases

Phase 1 · Tissue Collection and Primary Hepatoblast Isolation Day 0
  1. a Tissue Collection and Cold Storage
  2. b Tissue Mincing
  3. c Tissue Washing
  4. d Enzymatic Digestion
  5. e Digestion Arrest and Cell Recovery
  6. f Cell Filtration
  7. g Cell Pelleting and Washing (First Round)
Phase 2 · Human Fetal Liver Organoids Culture - Growth Factor Phase Day 0-7
  1. a Final Washing and Pellet Resuspension
  2. b Organoid Formation with Growth Factor Medium
  3. c GF-Medium Change (Days 1-7)
Phase 3 · Human Fetal Liver Organoids Culture - Chemical-Defined Phase Day 7 onwards
  1. a Medium Transition to Chemical-Defined Medium
  2. b 5C-Medium Refreshment (Day 7 onwards)
  3. c Organoid Cryopreservation (Optional)
Phase 4 · Lentiviral Vector Construction, Production, and Organoid Infection Day 7
  1. a Lentiviral Vector Plasmid Construction
  2. b HEK293T Cell Transfection for Lentivirus Production
  3. c Viral Supernatant Harvest
  4. d Viral Concentration
  5. e Lentivirus Infection of Organoids
Phase 5 · Immunofluorescence and Histological Analysis Variable (post-culture)
  1. a Organoid Fixation and Agarose Embedding
  2. b Paraffin Embedding
  3. c Tissue Sectioning
  4. d Section Hydration and Antigen Retrieval
  5. e Blocking and Primary Antibody Staining
  6. f Secondary Antibody Staining and Nuclear Counterstaining
  7. g Imaging
Phase 6 · Immunoblotting Analysis Variable (post-culture)
  1. a Sample Lysis and Protein Extraction
  2. b Protein Quantification
  3. c SDS-PAGE and Protein Transfer
  4. d Membrane Blocking
  5. e Primary Antibody Incubation
  6. f Membrane Washing and Secondary Antibody Incubation
  7. g Protein Detection and Imaging
Phase 7 · Functional Analysis of Fetal Liver Organoids Variable (post-culture)
  1. a LDL Uptake Assay
  2. b Bile Canaliculi Function Assay
Phase 8 · Mouse Xenograft Studies Variable (post-organoid culture)
  1. a Organoid Preparation for Transplantation
  2. b Orthotopic Liver Transplantation
Phase 9 · RNA Isolation and Quantitative Reverse Transcription PCR (qRT-PCR) Variable (post-culture)
  1. a Total RNA Extraction
  2. b Reverse Transcription
  3. c qRT-PCR Amplification
Phase 10 · High-Throughput Screening Day 7-12 (or Day 14-21)
  1. a Organoid Seeding in 96-Well Microplate
  2. b Chemical Compound Treatment
  3. c Nuclear Staining and Image Acquisition
  4. d Image Analysis
Phase 11 · mRNA Sequencing and Bioinformatic Analysis Variable (post-culture)
  1. a Total RNA Extraction and Library Preparation
  2. b Sequencing
  3. c Read Alignment and Transcript Quantification
  4. d Differential Expression Analysis
  5. e Heatmap Visualization and Clustering
Phase 12 · Organoid Hydrophilic Metabolite Extraction and Targeted Metabolomic Analysis Variable (post-culture)
  1. a Organoid Homogenization
  2. b Solvent Extraction (First Round)
  3. c First Centrifugation and Supernatant Collection
  4. d Solvent Extraction (Second Round)
  5. e Supernatant Pooling
  6. f Sample Aliquoting and Drying
  7. g Sample Storage
  8. h Sample Resuspension and Injection
  9. i Hydrophilic Interaction Chromatography (HILIC) Separation
  10. j Mass Spectrometry Data Acquisition
Phase 13 · Gene Set Enrichment Analysis (GSEA) Variable (post-sequencing)
  1. a Data Preparation for GSEA
  2. b GSEA Analysis with Custom Gene Sets
  3. c GSEA Result Interpretation
Phase 14 · Statistical Analysis and Data Presentation Variable (final analysis)
  1. a Statistical Testing
  2. b Data Presentation

Full SOP

Full SOPs need an account and a plan

Create an account, then get free Academic access (for verified academics) or choose a plan. Plans include step-by-step procedures, reagent concentrations, QC checklists and batch record templates.

Create an account

Already registered? Log in

Attribution

This SOP was written by Organthis based on the published method in Yang et al.. Once the originating laboratory has confirmed it, the SOP is marked Verified.

Something wrong with this entry? Report an issue with this protocol

Need a commercial licence?
Use this protocol in your therapeutic or diagnostic pipeline.
Request Commercial Licence